immune Cyclin-Dependent Protein Kinase
?Papulopustular rash could be a surrogate marker for efficacy of EGFRI treatment [10-12]. Introduction New chemotherapeutic brokers have the ability to specifically target malignancy cells. They assure an increased survival and less systemic toxicities, compared to conventional cytotoxic chemotherapies [1,2]. Despite this, targeted chemotherapies have numerous cutaneous adverse reactions, which may cause serious pain and negatively affect compliance to treatment. The presence and severity of cutaneous adver
immune CRF2 Receptors